A straightforward comparison of the two groups, using the differentially expressed genes for all 68 tumor samples (Figure 4E), did not identify any significantly enriched pathways, perhaps because of the dramatic heterogeneity within the good outcome group, which contained samples expressing MYB, MYBL1 and neither oncogene. This evidence concerns the gene MYBL1 and neoplasm.